The IUPAC name of<unk>  is 1-2-(dimethylamino)-1-(4 methoxyphenyl)ethylcyclohexanol, though it is sometimes referred to as (±)-1-a-a-(dimethylamino)methyl-p-methoxybenzylcyclohexanol. It consists of two enantiomers present in equal quantities (termed a racemic mixture), both of which have the empirical formula of C17H27NO2. It is usually sold as a mixture of the respective hydrochloride salts, (R/S)-1-2-(dimethylamino)-1-(4 methoxyphenyl)ethylcyclohexanol hydrochloride, C17H28ClNO2, which is a white to off-white crystalline solid.<unk>  is structurally and pharmacologically related to the atypical opioid analgesic tramadol, and more distantly to the newly released opioid tapentadol, but not to any of the conventional antidepressant drugs, including tricyclic antidepressants, SSRIs, MAOIs, or RIMAs.<unk>  extended release is chemically the same as normal<unk> . The extended release (controlled release) version distributes the release of the drug into the gastrointestinal tract over a longer period than normal<unk> . This results in a lower peak plasma concentration. Studies have shown that the extended release formula has a lower incidence of nausea as a side effect, resulting in better compliance.
Venlafaxine
Desvenlafaxine
Nortriptyline
Atomoxetine
Fluoxetine
Amitriptyline
Citalopram
Imipramine